Cite
Supplementary Table from Plasma Protein Biomarkers in Advanced or Metastatic Colorectal Cancer Patients Receiving Chemotherapy With Bevacizumab or Cetuximab: Results from CALGB 80405 (Alliance)
MLA
Herbert I. Hurwitz, et al. Supplementary Table from Plasma Protein Biomarkers in Advanced or Metastatic Colorectal Cancer Patients Receiving Chemotherapy With Bevacizumab or Cetuximab: Results from CALGB 80405 (Alliance). Mar. 2023. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....48adb960f441cc51d88179e4293b09fb&authtype=sso&custid=ns315887.
APA
Herbert I. Hurwitz, Kouros Owzar, Eileen M. O’Reilly, Jeffrey A. Meyerhardt, Federico Innocenti, Bert H. O’Neil, Heinz-Josef Lenz, Luis Baez-Diaz, Alan P. Venook, Donna Niedzwiecki, John C. Brady, Mark D. Starr, Flora Mulkey, Chen Jiang, Ace J. Hatch, Yingmiao Liu, Alexander B. Sibley, & Andrew B. Nixon. (2023). Supplementary Table from Plasma Protein Biomarkers in Advanced or Metastatic Colorectal Cancer Patients Receiving Chemotherapy With Bevacizumab or Cetuximab: Results from CALGB 80405 (Alliance).
Chicago
Herbert I. Hurwitz, Kouros Owzar, Eileen M. O’Reilly, Jeffrey A. Meyerhardt, Federico Innocenti, Bert H. O’Neil, Heinz-Josef Lenz, et al. 2023. “Supplementary Table from Plasma Protein Biomarkers in Advanced or Metastatic Colorectal Cancer Patients Receiving Chemotherapy With Bevacizumab or Cetuximab: Results from CALGB 80405 (Alliance),” March. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....48adb960f441cc51d88179e4293b09fb&authtype=sso&custid=ns315887.